Michael S. Turner Sells 7,148 Shares of 908 Devices Inc. (NASDAQ:MASS) Stock

908 Devices Inc. (NASDAQ:MASS - Get Free Report) insider Michael S. Turner sold 7,148 shares of the firm's stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $7.51, for a total transaction of $53,681.48. Following the transaction, the insider now owns 1,373 shares of the company's stock, valued at approximately $10,311.23. The trade was a 83.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Michael S. Turner also recently made the following trade(s):

• On Wednesday, June 18th, Michael S. Turner sold 1,373 shares of 908 Devices stock. The shares were sold at an average price of $7.50, for a total transaction of $10,297.50.

908 Devices Price Performance

Shares of 908 Devices stock traded down $0.63 on Friday, hitting $7.34. 2,836,094 shares of the company's stock traded hands, compared to its average volume of 1,041,277. The company has a fifty day moving average of $5.73 and a two-hundred day moving average of $3.87. 908 Devices Inc. has a one year low of $1.81 and a one year high of $8.06. The company has a market capitalization of $263.21 million, a price-to-earnings ratio of -13.59 and a beta of 0.29.

908 Devices (NASDAQ:MASS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.05. The firm had revenue of $11.78 million for the quarter, compared to analyst estimates of $11.90 million. 908 Devices had a negative return on equity of 27.10% and a negative net margin of 28.80%. Equities research analysts anticipate that 908 Devices Inc. will post -1.99 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of MASS. Concurrent Investment Advisors LLC acquired a new stake in 908 Devices in the fourth quarter worth $52,000. Prescott Group Capital Management L.L.C. bought a new position in shares of 908 Devices during the 4th quarter worth about $330,000. LPL Financial LLC boosted its position in shares of 908 Devices by 13.0% during the 4th quarter. LPL Financial LLC now owns 63,287 shares of the company's stock worth $139,000 after purchasing an additional 7,295 shares in the last quarter. Prudential Financial Inc. acquired a new stake in shares of 908 Devices in the 4th quarter valued at about $34,000. Finally, Geode Capital Management LLC increased its position in 908 Devices by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 581,300 shares of the company's stock valued at $1,279,000 after buying an additional 13,512 shares in the last quarter. Institutional investors and hedge funds own 88.06% of the company's stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of 908 Devices in a research note on Wednesday, June 11th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $5.33.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.